BioRender 아이콘

Neuroblastoma (SH-SY5Y, differentiated 1)

Neuroblastoma (SH-SY5Y, differentiated 1) - Editable icon of A differentiated SH-SY5Y neuroblastoma with a budding axon and a pyramidal body
[{"image":"https://icons.cdn.biorender.com/w75xh75/630637837c75bb00281a695f/6306370e7c75bb00281a68fb.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630637837c75bb00281a695f/6306370e7c75bb00281a68fb.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630637837c75bb00281a695e/6306370e7c75bb00281a68fb.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630637837c75bb00281a695e/6306370e7c75bb00281a68fb.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630637837c75bb00281a695d/6306370e7c75bb00281a68fb.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630637837c75bb00281a695d/6306370e7c75bb00281a68fb.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630637837c75bb00281a695c/6306370e7c75bb00281a68fb.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630637837c75bb00281a695c/6306370e7c75bb00281a68fb.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630637837c75bb00281a695b/6306370e7c75bb00281a68fb.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630637837c75bb00281a695b/6306370e7c75bb00281a68fb.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630637837c75bb00281a695a/6306370e7c75bb00281a68fb.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630637837c75bb00281a695a/6306370e7c75bb00281a68fb.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630637837c75bb00281a6959/6306370e7c75bb00281a68fb.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630637837c75bb00281a6959/6306370e7c75bb00281a68fb.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630637837c75bb00281a6958/6306370e7c75bb00281a68fb.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630637837c75bb00281a6958/6306370e7c75bb00281a68fb.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630637837c75bb00281a6957/6306370e7c75bb00281a68fb.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630637837c75bb00281a6957/6306370e7c75bb00281a68fb.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630637837c75bb00281a6956/6306370e7c75bb00281a68fb.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630637837c75bb00281a6956/6306370e7c75bb00281a68fb.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630637837c75bb00281a6955/6306370e7c75bb00281a68fb.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630637837c75bb00281a6955/6306370e7c75bb00281a68fb.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630637837c75bb00281a6954/6306370e7c75bb00281a68fb.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630637837c75bb00281a6954/6306370e7c75bb00281a68fb.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630637837c75bb00281a6953/6306370e7c75bb00281a68fb.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630637837c75bb00281a6953/6306370e7c75bb00281a68fb.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630637837c75bb00281a6952/6306370e7c75bb00281a68fb.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630637837c75bb00281a6952/6306370e7c75bb00281a68fb.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630637837c75bb00281a6951/6306370e7c75bb00281a68fb.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630637837c75bb00281a6951/6306370e7c75bb00281a68fb.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630637837c75bb00281a6950/6306370e7c75bb00281a68fb.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630637837c75bb00281a6950/6306370e7c75bb00281a68fb.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630637837c75bb00281a694f/6306370e7c75bb00281a68fb.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630637837c75bb00281a694f/6306370e7c75bb00281a68fb.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630637837c75bb00281a694e/6306370e7c75bb00281a68fb.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630637837c75bb00281a694e/6306370e7c75bb00281a68fb.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630637837c75bb00281a694d/6306370e7c75bb00281a68fb.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630637837c75bb00281a694d/6306370e7c75bb00281a68fb.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630637837c75bb00281a694c/6306370e7c75bb00281a68fb.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630637837c75bb00281a694c/6306370e7c75bb00281a68fb.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630637837c75bb00281a694b/6306370e7c75bb00281a68fb.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630637837c75bb00281a694b/6306370e7c75bb00281a68fb.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630637837c75bb00281a694a/6306370e7c75bb00281a68fb.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630637837c75bb00281a694a/6306370e7c75bb00281a68fb.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630637837c75bb00281a6949/6306370e7c75bb00281a68fb.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630637837c75bb00281a6949/6306370e7c75bb00281a68fb.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630637837c75bb00281a6948/6306370e7c75bb00281a68fb.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630637837c75bb00281a6948/6306370e7c75bb00281a68fb.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630637837c75bb00281a6947/6306370e7c75bb00281a68fb.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630637837c75bb00281a6947/6306370e7c75bb00281a68fb.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630637837c75bb00281a6946/6306370e7c75bb00281a68fb.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630637837c75bb00281a6946/6306370e7c75bb00281a68fb.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630637837c75bb00281a6945/6306370e7c75bb00281a68fb.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630637837c75bb00281a6945/6306370e7c75bb00281a68fb.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630637837c75bb00281a6944/6306370e7c75bb00281a68fb.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630637837c75bb00281a6944/6306370e7c75bb00281a68fb.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630637837c75bb00281a6943/6306370e7c75bb00281a68fb.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630637837c75bb00281a6943/6306370e7c75bb00281a68fb.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630637837c75bb00281a6942/6306370e7c75bb00281a68fb.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630637837c75bb00281a6942/6306370e7c75bb00281a68fb.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630637837c75bb00281a6941/6306370e7c75bb00281a68fb.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630637837c75bb00281a6941/6306370e7c75bb00281a68fb.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630637837c75bb00281a6940/6306370e7c75bb00281a68fb.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630637837c75bb00281a6940/6306370e7c75bb00281a68fb.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630637837c75bb00281a693f/6306370e7c75bb00281a68fb.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630637837c75bb00281a693f/6306370e7c75bb00281a68fb.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630637837c75bb00281a693e/6306370e7c75bb00281a68fb.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630637837c75bb00281a693e/6306370e7c75bb00281a68fb.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630637837c75bb00281a693d/6306370e7c75bb00281a68fb.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630637837c75bb00281a693d/6306370e7c75bb00281a68fb.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630637837c75bb00281a693c/6306370e7c75bb00281a68fb.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630637837c75bb00281a693c/6306370e7c75bb00281a68fb.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630637837c75bb00281a693b/6306370e7c75bb00281a68fb.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630637837c75bb00281a693b/6306370e7c75bb00281a68fb.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630637837c75bb00281a693a/6306370e7c75bb00281a68fb.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630637837c75bb00281a693a/6306370e7c75bb00281a68fb.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630637837c75bb00281a6939/6306370e7c75bb00281a68fb.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630637837c75bb00281a6939/6306370e7c75bb00281a68fb.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630637837c75bb00281a6938/6306370e7c75bb00281a68fb.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630637837c75bb00281a6938/6306370e7c75bb00281a68fb.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630637837c75bb00281a6937/6306370e7c75bb00281a68fb.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630637837c75bb00281a6937/6306370e7c75bb00281a68fb.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630637837c75bb00281a6936/6306370e7c75bb00281a68fb.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630637837c75bb00281a6936/6306370e7c75bb00281a68fb.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630637837c75bb00281a6935/6306370e7c75bb00281a68fb.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630637837c75bb00281a6935/6306370e7c75bb00281a68fb.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630637837c75bb00281a6934/6306370e7c75bb00281a68fb.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630637837c75bb00281a6934/6306370e7c75bb00281a68fb.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630637837c75bb00281a6933/6306370e7c75bb00281a68fb.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630637837c75bb00281a6933/6306370e7c75bb00281a68fb.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630637837c75bb00281a6932/6306370e7c75bb00281a68fb.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630637837c75bb00281a6932/6306370e7c75bb00281a68fb.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630637837c75bb00281a6931/6306370e7c75bb00281a68fb.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630637837c75bb00281a6931/6306370e7c75bb00281a68fb.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630637837c75bb00281a6930/6306370e7c75bb00281a68fb.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630637837c75bb00281a6930/6306370e7c75bb00281a68fb.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630637837c75bb00281a692f/6306370e7c75bb00281a68fb.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630637837c75bb00281a692f/6306370e7c75bb00281a68fb.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630637837c75bb00281a692e/6306370e7c75bb00281a68fb.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630637837c75bb00281a692e/6306370e7c75bb00281a68fb.png"}]
이 아이콘 사용하기 – 무료
가입 시 신용카드가 필요하지 않습니다.

이 아이콘은 BioRender에서 자유롭게 편집할 수 있습니다

  • 텍스트, 도형 및 기타 아이콘 추가
  • 5만 개 이상의 과학적으로 정확한 아이콘을 검색하세요
  • 모든 아이콘, 선, 라벨의 색상과 배치를 자유롭게 변경하세요
  • 어떤 용도로든 내보내거나 공유하세요
Scientist Avatars

이미 출판용 수준의 그림을 만들고 있는 400만 명 이상의 과학자들과 함께하세요

아이콘으로 몇 분 만에 완성된 그림을 만들어 보세요

  • 검색 50,000개 이상의 과학적으로 정확하고 동료 검토를 거친 아이콘 제공
  • 맞춤 설정 라벨, 도형, 추가 아이콘을 사용하여 모든 요소를 자유롭게 편집할 수 있습니다.
  • 내보내기 또는 공동 작업자와 그림 공유하기
    ‍

찾으시는 아이콘이 아닌가요? 더 많은 아이콘을 확인해 보세요.

30개 이상의 생명과학 분야에 걸친 50,000개 이상의 아이콘을 검색하세요.

search icon
arrow-right
neuroblastoma,SH-sy5y,SK-N-SH,parkinson,neurogenesis,differentiated,differentiation,n type,SH-sy5y
더 보기

동의어를 검색하거나 가입하여 앱에서 아이콘을 요청해 보세요.

이미지 유형

Neuroblastoma (SH-SY5Y, differentiated 1) icon JPEG

Neuroblastoma (SH-SY5Y, differentiated 1) icon PNG

Neuroblastoma (SH-SY5Y, differentiated 1) icon SVG

Neuroblastoma (SH-SY5Y, differentiated 1) icon GIF

BioRender 아이콘 FAQ

How are scientists using the Neuroblastoma (SH-SY5Y, differentiated 1) icon in their work?

BioRender users often use the Neuroblastoma (SH-SY5Y, differentiated 1) icon in posters, grant applications, educational materials, and graphical abstracts. It’s especially useful for projects involving Cell Types.

이 아이콘을 BioRender 그림이나 과학 일러스트레이션에 사용할 수 있나요?

Yes, the Neuroblastoma (SH-SY5Y, differentiated 1) is fully integrated into BioRender’s drag-and-drop platform. You can easily add it to any scientific figure, workflow, or poster, whether you’re building from scratch or starting with a BioRender template.

Is the Neuroblastoma (SH-SY5Y, differentiated 1) icon customizable in BioRender?

Most icons in BioRender, including the Neuroblastoma (SH-SY5Y, differentiated 1) icon, are customizable. You can adjust icon size, colors, and positioning, and add custom labels to tailor the design to your specific research context.

Can I export figures that include the Neuroblastoma (SH-SY5Y, differentiated 1) icon for publication or presentations?

Yes, figures containing the Neuroblastoma (SH-SY5Y, differentiated 1) icon can be exported in multiple formats, including PNG, JPG, PDF, and SVG. High-resolution and vector exports are available on paid plans, making them ideal for journals, slide decks, and print materials.

How do I cite BioRender if I use this icon?

Unlock publication permissions with a paid plan, and include 'Created with BioRender.com' in your figure legend, or cite BioRender directly per your journal's guidelines.

Is the Neuroblastoma (SH-SY5Y, differentiated 1) icon used in BioRender templates or poster layouts?

Many BioRender templates include icons like the Neuroblastoma (SH-SY5Y, differentiated 1) icon — especially those focused on Cell Types. You can search BioRender’s template library or add this icon manually to any canvas.

BioRender란 무엇인가요?

BioRender is a web‑based software that helps you create scientific figures in minutes. Use this Neuroblastoma (SH-SY5Y, differentiated 1) icon along with our library of more than 30,000 life science icons.

BioRender에서 이 아이콘 사용하기

지금 바로 전문가 수준의 과학 피규어를 만들어 보세요
antibody elements3D Phospholipid illustration

과학 콘텐츠를 찾고 계신가요?

동료 검토를 거쳐 사용하기 쉽고 무료로 제공되는 5만 개 이상의 아이콘과 템플릿을 살펴보세요.

지금 바로 찾아보세요
x icon